Cancer clinical trials test new treatments in a structured, multi-phase process designed to determine whether a drug or therapy is safe, effective, and better than what’s currently available. Each phase builds on the last, starting with small safety tests and ending with large-scale comparisons against standard treatment. Only about 13% of cancer drugs that enter clinical trials ultimately receive FDA approval, so the process is long and rigorous by design.
The Four Phases of Cancer Trials
Phase 1 trials are the first time a new treatment is tested in people. The goal is straightforward: figure out whether the treatment is safe, identify side effects, and find the highest dose the body can tolerate. These trials are small, typically involving 15 to 30 participants. Researchers also look for early signs that the treatment affects the cancer, but safety is the priority.
Phase 2 expands the group to roughly 50 to 100 people and shifts focus toward whether the treatment actually works. Researchers look for measurable results like tumors shrinking or cancer growth slowing. Side effects continue to be tracked closely. If a treatment shows promise here, it moves forward.
Phase 3 is where the real comparison happens. Hundreds to several thousand participants are enrolled, and the new treatment is tested head-to-head against the current standard therapy. Participants are randomly assigned to receive either the new treatment or the existing one. This randomization is critical because it ensures that any differences in outcomes are caused by the treatment itself, not by differences between the people in each group. Phase 3 results are what the FDA primarily relies on when deciding whether to approve a new drug.
Phase 4 trials happen after a treatment has already been approved and is available to the public. These studies monitor long-term safety and effectiveness in larger, more diverse groups of people over months or years. Problems that were too rare to appear in earlier phases sometimes surface here.
How Randomization and Blinding Reduce Bias
Randomization means you don’t get to choose which treatment group you’re placed in, and neither does your doctor. A computer assigns you to a group. This prevents the kind of subtle selection bias that could skew results, like sicker patients ending up in one group more than another.
Blinding takes this a step further. In a blinded trial, you don’t know which treatment you’re receiving. In a double-blinded trial, your doctor doesn’t know either. This matters because expectations can influence how both patients and researchers perceive and report results. If you know you’re getting the experimental drug, you might interpret your symptoms differently. If your doctor knows, they might unconsciously assess your progress differently.
Blinding isn’t always possible in cancer trials. When one treatment is a pill and the other is an infusion, or when one involves surgery and the other doesn’t, it becomes obvious which group you’re in. In those cases, researchers rely more heavily on objective measures like tumor size on imaging scans rather than subjective reports.
Placebos in cancer trials are handled differently than in many other fields. You will not be given a sugar pill instead of treatment when an effective standard therapy already exists. Instead, the comparison group typically receives the best currently available treatment. Placebos are only used when no proven treatment exists for that specific situation, or they’re added on top of standard care (so everyone gets real treatment, but one group also gets the experimental drug).
Who Can Join a Cancer Trial
Every trial has eligibility criteria that define who can and can’t participate. These aren’t arbitrary restrictions. They exist to create a study population that’s similar enough to produce meaningful results, and to protect people from treatments that might be especially risky for them.
Common inclusion factors are the type and stage of cancer, your overall physical fitness (measured by a standardized performance status score), specific genetic mutations in your tumor, and what treatments you’ve already tried. Many trials require that you haven’t had another type of cancer within the past three to five years. Exclusion criteria often include certain infections like HIV or hepatitis B, active autoimmune diseases, and some psychiatric conditions.
These criteria vary widely from trial to trial. A trial studying a drug that targets a specific gene mutation will only enroll patients whose tumors carry that mutation. A trial for a broadly acting immunotherapy might have much wider enrollment. If you’re turned down for one trial, you may still qualify for others.
Newer Trial Designs in Cancer Research
Traditional trials test one drug for one type of cancer. Newer designs are more flexible and can produce answers faster.
- Basket trials test a single targeted therapy across multiple cancer types that share the same molecular change. If a lung cancer, a breast cancer, and a colon cancer all have the same genetic mutation, they can all be studied in one trial.
- Umbrella trials work in the opposite direction. They focus on one type of cancer but divide patients into subgroups based on their tumor’s molecular profile, then test different targeted treatments in each subgroup.
- Platform trials test multiple treatments against a shared control group and can evolve over time. If one treatment arm isn’t working, it gets dropped. If a promising new drug becomes available, it can be added to the trial without starting over from scratch.
These designs reflect the broader shift toward precision medicine, where treatment decisions are based on the genetic characteristics of a tumor rather than just where in the body it originated.
Your Rights as a Participant
Before you enroll in any trial, you go through a process called informed consent. This is more than signing a form. The research team is required to explain, in language you can understand, exactly what the study involves: its purpose, how long it will last, what procedures are experimental, and what the known risks and potential benefits are. They must also tell you about alternative treatments available outside the trial.
The consent document must describe how your medical records will be kept confidential, whether compensation or medical treatment is available if you’re injured during the study, and who to contact with questions. It cannot include any language that waives your legal rights or releases the researchers from liability.
Participation is voluntary, and you can leave a trial at any time for any reason without losing access to your regular medical care or benefits. No penalty, no pressure.
Who Watches Over Trial Safety
Two layers of oversight protect participants. Institutional Review Boards (IRBs) are independent committees that review every trial before it begins. An IRB has the authority to approve a study, require changes, or shut it down entirely. Their job is to ensure participants’ rights and welfare are protected, and they review the trial protocol, the informed consent documents, and safety data on an ongoing basis throughout the study.
The FDA provides a second layer of oversight, setting regulations for how trials must be conducted and monitoring compliance. Serious or unexpected side effects must be reported quickly under standardized safety reporting rules. If a treatment turns out to be dangerous, or if it’s working so well that it would be unethical to keep giving some patients the standard treatment, a trial can be stopped early.
What It Costs to Participate
The costs of a clinical trial are split into two categories. Patient care costs are the expenses you’d face even if you weren’t in a trial: doctor visits, hospital stays, standard cancer treatments, lab tests, and imaging scans. These are typically covered by your health insurance the same way they would be for regular care.
Research costs cover everything that exists only because of the trial: the experimental drug itself, extra lab work done purely for research purposes, additional imaging tests, and extra doctor visits beyond your normal schedule. These costs are usually paid by the trial’s sponsor, whether that’s a pharmaceutical company, a government agency, or an academic institution.
Travel, lodging, meals, and parking are a gray area. Some trials offer financial assistance for these expenses or can connect you with support organizations that help. It’s worth asking the research team directly what’s available before you enroll.
How to Find a Cancer Clinical Trial
ClinicalTrials.gov, maintained by the National Library of Medicine, is the most comprehensive database of clinical studies worldwide. You can search by cancer type, location, study status (recruiting vs. not yet recruiting), and other filters. Each study has a detailed record with eligibility criteria, locations, and contact information. The site also offers patient resources that explain how to read study records and interpret results.
The National Cancer Institute runs its own trial search tool focused specifically on cancer studies, which can be easier to navigate if you’re not familiar with clinical research terminology. Many major cancer centers also maintain lists of trials they’re actively enrolling for, and your oncologist can help identify trials that match your specific diagnosis and treatment history.